

GALECTIN THERAPEUTICS INC

Form 8-K

March 31, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 31, 2014**

**GALECTIN THERAPEUTICS INC.**

**(Exact name of registrant as specified in its charter)**

**Nevada**  
**(State or Other Jurisdiction**

**001-31791**  
**(Commission**

**04-3562325**  
**(IRS Employer**

**of Incorporation)**

**File Number)**

**Identification No.)**

**4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240**

**NORCROSS, GA 30071**

**(Address of principal executive office) (zip code)**

**Registrant's telephone number, including area code: (678) 620-3186**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **SECTION 8 OTHER ITEMS**

### **Item 8.01 Other Items.**

On March 31, 2014, Galectin Therapeutics Inc. posted a presentation on its website that contains a summary of the results of the first cohort of patients in the Phase 1 clinical trial, which is attached as Exhibit 99.1, and issued the attached press release.

## **SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS**

### **Item 9.01 Financial Statements and Exhibits.**

#### **(a) Financial Statements of Businesses Acquired.**

Not applicable.

#### **(b) Pro Forma Financial Information.**

Not applicable.

#### **(c) Shell Company Transactions.**

Not applicable.

#### **(d) Exhibits.**

Exhibit Number	Description
99.1	Presentation on Phase 1 Clinical Trial: Results of First Cohort
99.2	Press Release dated March 31, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

Date: March 31, 2014

By: /s/ Jack W. Callicutt  
Jack W. Callicutt  
Chief Financial Officer

- 3 -